In vitro activity of ertapenem against bacterial isolates from cancer patients

Diagnostic Microbiology and Infectious Disease

Volumn 43, Issue 3, 2002, Pages 219-223

  Rolston, Kenneth V I ^a   LeBlanc, Barbara M ^a   Streeter, Harriet ^a   Ho, Dah H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; ERTAPENEM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM COLONY; BACTERIUM ISOLATION; BLOOD CULTURE; CANCER PATIENT; CONFERENCE PAPER; CONTROLLED STUDY; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; LACTAMS; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 0036063131     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00395-4     Document Type: Conference Paper

References (21)

1. Infection in cancer patients: A continuing association
2. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
3. In vitro activities of Ertapenem (MK-0826) against clinical bacterial isolates from 11 North American Medical Centers
4. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345)
5. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
6. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
7. The MASCC Risk Index: A multinational scoring system to predict low-risk febrile neutropenic cancer patients
8. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates
9. In vitro activities of Ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia
10. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial
11. Outpatient treatment of febrile neutropenia in low risk pediatric cancer patients
12. Management of fever in patients with cancer and treatment induced neutropenia
13. New trends in patient management: Risk-based therapy for febrile patients with neutropenia
14. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer
15. Ambulatory management of febrile episodes in low risk neutropenic patients
16. Early empiric antibiotic therapy for febrile neutropenia patients at "low-risk."
17. Risk-adjusted management of the febrile neutropenic cancer patient
18. Outpatient treatment of febrile episodes in low risk neutropenic cancer patients
19. Risk assessment in cancer patients with fever and neutropenia. A prospective, two-center validation of a prediction rule